Backs FY25 revenue view 6.7%-7.7%. The company said, “The Company is maintaining reported revenue growth and adjusted2 earnings per share guidance and narrowing full-year 2025 constant currency and organic constant currency revenue growth guidance to reflect currency expectations.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet price target lowered to $105 from $112 at Barclays
- Notable companies reporting before tomorrow’s open
- ZBH Upcoming Earnings Report: What to Expect?
- Zimmer Biomet: FDA grants BDD for iodine-treated total hip replacement system
- Zimmer Biomet: FDA grants BDD for treated total hip replacement system